When it comes to labeling unexpected events during a clinical trial, most investigators agree: The answer isn’t always obvious. The definitions – and the required responses -- vary from one agency to the next.

And the reporting process only adds more stress. Misjudge a problem and you’ll pay a steep price for failure to report to the FDA.

Clinical Trials Adverse Event Reporting Reference Guide is the most up-to-date, comprehensive collection of rules, regulations and guidances available in a murky area where change happens fast.

The first edition of the Guide sold out. But, that was three years ago. Look at all that has changed:

• A newly issued guidance from OHRP on IRB Continuing Review of Research

• Another new guidance on Reporting Incidents to OHRP

• A new FDA guidance, Safety Reporting Requirements for INDs and BA/BE Studies

• Plus numerous new enforcement cases involving adverse event reporting

Order Today

The Clinical Trials Adverse Event Reporting Reference Guide, Second Edition provides official OHRP and FDA answers to nagging questions, including:

• How to determine if an adverse event needs to be reported

• When does an expected adverse event become an unanticipated adverse event

• How do adverse events differ from unanticipated problems

• How to assess if an event is unexpected

• How to assess whether an event is related to research

• What needs to be included in adverse event reports

• And much more

Also featured — analysis of relevant warning letters, illustrating ways adverse event reporting requirements often are misconstrued or overlooked.

Whether you’re in drugs or devices ... a CRO or a clinical trial site operator ... the Clinical Trials Adverse Event Reporting Reference Guide, Second Edition belongs on your bookshelf or desk, in easy reach. When those tough calls arise, you’ll find yourself referring to it again and again.

Buy Now!
Clinical Trials Adverse Event Reporting Reference Guide, Second Edition is available in print (200+ pp.) or PDF format for $377 each. Act now: place your order here.

Satisfaction Guaranteed
There's no risk when you purchase from FDAnews with our money-back guarantee. Not satisfied with your publication? Return the hard copy within 30 days (in resalable condition), and we will refund 100 percent of your purchase price (less shipping/handling). For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase to receive a refund.